COMMUNIQUÉS West-GlobeNewswire

-
Decisions taken by Orion Corporation’s Annual General Meeting on 3 April 2025
03/04/2025 -
Hapbee Announces Partnership with Gharieni Group To License and Distribute Hapbee’s Wellness Technology in Europe and The Middle East
03/04/2025 -
Vantive Chief Strategy Officer Joins Labviva Board
03/04/2025 -
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
03/04/2025 -
SPARK NS Selects Eight Projects to Receive Aggregate Funding of Up to $16 Million to Advance Academic Discoveries in Parkinson’s Disease from the Lab to the Clinic
03/04/2025 -
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US
03/04/2025 -
Precision Optics Enters into Main Purchase Agreement with Top Tier Aerospace Customer and Expands Program Backlog to $6.6 Million
03/04/2025 -
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
03/04/2025 -
Ernexa Therapeutics Closes New Funding Round
03/04/2025 -
Winstrol Steroids: Winstrol Benefits, Winstrol Side Effects, Winstrol Results & Buy Winstrol Pills Alternatives Win-Max By CrazyBulk
03/04/2025 -
Globus Medical completes acquisition of Nevro Corp.
03/04/2025 -
NewGen Secures Strategic Funding to Drive International Expansion and Corporate Growth
03/04/2025 -
Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)
03/04/2025 -
Scienture Holdings, Inc. Issues Annual Letter to Shareholders
03/04/2025 -
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
03/04/2025 -
Elutia to Participate in Upcoming Investor Conferences
03/04/2025 -
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
03/04/2025 -
BetterLife Pharma Appoints Corporate Advisor
03/04/2025 -
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline
03/04/2025
Pages